Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Technology
Share your love
Peptide Eye Drops Offer Hope for Dry AMD
Researchers from the Natural Product Drug Development Center at the Korea Institute of Science and Technology (KIST), led by Dr. Moon-Hyeong Seo, have developed an innovative therapeutic agent for dry age-related macular degeneration (AMD) in the form of peptide-based eye…
MicroPulse TLT Proven Effective for Glaucoma
Iridex Corporation, a global leader in laser-based medical systems for glaucoma and retinal disease treatment, has announced the publication of a groundbreaking peer-reviewed study in Ophthalmology Therapy. The study provides compelling evidence of the long-term safety and efficacy of MicroPulse…
4DMT Reveals Preclinical Data on TVE Platform
4D Molecular Therapeutics (4DMT) has announced the publication of preclinical data underscoring the capabilities of its Therapeutic Vector Evolution (TVE) platform. The research focuses on the intravitreal R100 vector and the R100-based genetic medicine 4D-150. This groundbreaking study, titled “Design…
FDA Clears ViGeneron’s VG801 for Stargardt Disease
The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for VG801, ViGeneron’s novel gene therapy candidate designed to treat Stargardt disease and other retinal dystrophies caused by mutations in the ABCA4 gene. This marks…
2023 Recap: Top 15 Research in Ophthalmology
2024 Recap is here! Click to review:Top 10 Breakthroughs in Ophthalmology Research In the fast-evolving landscape of ophthalmology research, 2023 has proven to be a pivotal year marked by groundbreaking discoveries and innovation. From revolutionary cell replacement therapies to novel…
Atsena Completes XLRS Gene Therapy Trial Dosing
Atsena Therapeutics has successfully completed dosing in Part A of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating the subretinal delivery of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The study represents an important step forward in developing…
Phenocell & Amarna Win Eurostars Grant
Phenocell SAS and Amarna Therapeutics have been awarded the prestigious Eurostars grant to advance their collaborative gene therapy platform targeting dry age-related macular degeneration (AMD). This partnership combines Phenocell’s innovative in vitro AMD disease model with Amarna’s proprietary gene delivery…
Nona Biosciences, Kodiak Partner on Ophthalmic Antibodies
Nona Biosciences has announced a strategic partnership with Kodiak Sciences Inc. to advance the development of innovative multi-target antibodies for treating ophthalmic diseases. This collaboration leverages Nona’s proprietary Harbour Mice platform, a cutting-edge technology designed to generate fully human antibodies,…
ViaLase, Moran Eye Center Collaborate on Glaucoma
ViaLase has announced a groundbreaking research partnership with the John A. Moran Eye Center at the University of Utah, home to the Alan S. Crandall Center for Glaucoma Innovation. This collaboration aims to accelerate glaucoma research by utilizing Moran’s state-of-the-art…
First Inverted Meniscus Optics IOLs by Voptica
*This exclusive article is sponsored by Voptica. The opinions expressed in this article are the sponsor’s own. Intraocular lenses (IOLs) designs are constantly evolving to improve patients’ vision needs. Trifocal diffractive IOLs are designed to achieve good visual acuity at…